NeoGenomics, Inc.
NeoGenomics, Inc. (NEO) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
neo · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for NeoGenomics, Inc. (NEO) measures how much investors pay for each dollar of the company's trailing earnings. NEO's current PE ratio of N/A is calculated by dividing its stock price of $10.95 by its TTM earnings per share of -$3.84.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 6 fiscal years · Front-end computedMinQ1 · 25%80.4x
MedianQ3 · 75%371.8x
Max
At N/A, NEO's current P/E is lower than in 0% of its annual fiscal year readings over the past 6 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Medical - Diagnostics & Research · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
NeoGenomics, Inc.You NEO | $285M | N/A | — | -$3.84 |
 Aclaris Therapeutics, Inc. ACRS | $526M | N/A | — | -$0.53 |
 Arcturus Therapeutics Holdings Inc. ARCT | $209M | N/A | — | -$2.40 |
 Humacyte, Inc. HUMA | $244M | N/A | — | -$0.26 |
 MDxHealth S.A. MDXH | $30M | N/A | — | -$0.67 |
 Quanterix Corporation QTRX | $147M | N/A | — | -$2.51 |
 Sagimet Biosciences Inc. SGMT | $218M | N/A | — | -$1.58 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-4.22 | — | |
2024-12-31 FY2024 | — | $-3.11 | — | |
2023-12-31 FY2023 | — | $-3.50 | — | |
2022-12-31 FY2022 | — | $-5.81 | — | |
2021-12-31 FY2021 | — | $-0.35 | — | |
2020-12-31 FY2020 | 280.24x | $0.19 | +281.7% | |
2019-12-31 FY2019 | 73.41x | $0.40 | -16.1% | |
2018-12-31 FY2018 | 87.48x | $0.14 | — | |
2017-12-31 FY2017 | — | $-0.02 | — | |
2016-12-31 FY2016 | — | $-0.39 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for NeoGenomics, Inc. (NEO) measures how much investors pay for each dollar of the company's trailing earnings. NEO's current PE ratio of N/A is calculated by dividing its stock price of $10.95 by its TTM earnings per share of -$3.84.
Frequently asked questions
NEO pe ratio · 6 questionsNEO's current PE ratio is N/A as of 2026-06-09, based on a stock price of $10.95 and TTM EPS of -$3.84. Data sourced from Financial Modeling Prep via NEO's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · NeoGenomics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09